Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1203mxm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS 3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS 4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents
NEWS 6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS 7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS 8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS 9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS 10	NOV 23	Addition of SCAN format to selected STN databases
NEWS 11	NOV 23	Annual Reload of IFI Databases
NEWS 12	DEC 01	FRFULL Content and Search Enhancements
NEWS 13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS 14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS 15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS 16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial

gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:04:07 ON 14 DEC 2009

=>
=> file reg

=>
Uploading C:\Program Files\Stnexp\Queries\11595792.str



chain nodes :
10 15 16 17
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14
ring/chain nodes :
18
chain bonds :
3-10 8-15 15-16 16-17 17-18
ring bonds :
1-2 1-6 1-14 2-3 3-4 4-5 4-7 5-6 5-9 6-11 7-8 8-9 11-12 12-13 13-14
exact/norm bonds :
1-6 1-14 3-10 4-7 5-9 6-11 7-8 8-9 8-15 11-12 12-13 13-14 15-16 16-17
17-18
normalized bonds :
1-2 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sam
SAMPLE SEARCH INITIATED 15:04:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      584 TO ITERATE

100.0% PROCESSED      584 ITERATIONS                          24 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        10231 TO    13129
PROJECTED ANSWERS:             187 TO      773

L2           24 SEA SSS SAM L1

=> d scan

L2   24 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   Benzoic acid, 4-[[[[4-amino-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-
     yl]methoxy]imino]methyl]-, methyl ester
MF   C24 H25 N5 O3
CI   COM
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Carbamic acid, [[4-amino-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methoxy]-, methyl ester, mono(trifluoroacetate) (salt) (9CI)
MF C17 H21 N5 O4 . C2 H F3 O2

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN Acetamide, N-[2-[4-amino-2-[[[(1-methylethylidene)amino]oxy]methyl]-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-2-phenoxy-
MF C24 H26 N6 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[[4-amino-6,7,8,9-tetrahydro-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methoxy]-3,4-dichloro-, 2,2,2-trifluoroacetate (1:1)
MF C22 H25 Cl2 N5 O2 . C2 H F3 O2

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4-Piperidinone, 1-(phenylmethyl)-,
O-[[4-amino-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methyl]oxime
MF C27 H32 N6 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propanone, O-[[4-amino-1-(2-aminoethyl)-1H-imidazo[4,5-c]quinolin-2-yl]methyl]oxime
MF C16 H20 N6 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propanone, O-[[4-amino-7-[4-(dimethylamino)phenyl]-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methyl]oxime
MF C26 H32 N6 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetaldehyde, O-[[4-amino-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methyl]oxime, 2,2,2-trifluoroacetate (1:?)
MF C17 H21 N5 O . x C2 H F3 O2

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Methanesulfonamide, N-[4-[4-amino-2-[[(cyclopentylideneamino)oxy]methyl]-1H-imidazo[4,5-c]quinolin-1-yl]butyl]-
MF C21 H28 N6 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzaldehyde, 2-fluoro-, O-[[4-amino-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methyl]oxime, 2,2,2-trifluoroacetate (1:?)
MF C22 H22 F N5 O . x C2 H F3 O2

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclopentanepropanamide, N-[[4-amino-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methoxy]-, 2,2,2-trifluoroacetate (1:1)
MF C23 H31 N5 O2 . C2 H F3 O2

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzaldehyde, 4-methoxy-, O-[[4-amino-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methyl]oxime
MF C23 H25 N5 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetamide, N-[[4-amino-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methoxy]-
MF C17 H21 N5 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Pentanamide, N-[2-[4-amino-2-[[[(1-methylethylidene)amino]oxy]methyl]-1H-imidazo[4,5-c]quinolin-1-yl]ethyl]-, 2,2,2-trifluoroacetate (1:?)
MF C21 H28 N6 O2 . x C2 H F3 O2

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[[4-amino-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methoxy]-3,4-dichloro-

MF C22 H21 Cl2 N5 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclopentanepropanamide, N-[3-[4-amino-2-[[[(1-methylethylidene)amino]oxy]methyl]-1H-imidazo[4,5-c]quinolin-1-yl]propyl]-
MF C25 H34 N6 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propanone, O-[[4-amino-1-(3-aminopropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methyl]oxime, 2,2,2-trifluoroacetate (1:5)
MF C17 H22 N6 O . 5 C2 H F3 O2

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propanone, O-[[4-amino-1-(2-methylpropyl)-7-(3-pyridinyl)-1H-imidazo[4,5-c]quinolin-2-yl]methyl]oxime, 2,2,2-trifluoroacetate (1:?)
MF C23 H26 N6 O . x C2 H F3 O2

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propanone, O-[[4-amino-7-bromo-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methyl]oxime
MF C18 H22 Br N5 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propanone, O-[[4-amino-7-[4-(1-methylethoxy)phenyl]-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methyl]oxime
MF C27 H33 N5 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Furancarboxaldehyde, O-[[4-amino-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methyl]oxime
MF C20 H21 N5 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 H32 N6 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenepropanal, O-[[4-amino-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methyl]oxime, 2,2,2-trifluoroacetate (1:?)

MF C24 H27 N5 O . x C2 H F3 O2

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 24 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[[4-amino-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methoxy]-3-methoxy-, 2,2,2-trifluoroacetate (1:1)
MF C23 H25 N5 O3 . C2 H F3 O2

CM 1



CM 2



ALL ANSWERS HAVE BEEN SCANNED

```
=> l
1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d his

     (FILE 'HOME' ENTERED AT 15:04:07 ON 14 DEC 2009)

     FILE 'REGISTRY' ENTERED AT 15:04:19 ON 14 DEC 2009
L1             STRUCTURE UPLOADED
L2          24 S L1 SAM

=> s l1 full
FULL SEARCH INITIATED 15:05:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    11426 TO ITERATE

100.0% PROCESSED    11426 ITERATIONS                          476 ANSWERS
SEARCH TIME: 00.00.02

L3          476 SEA SSS FUL L1

=> file ca

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4           2 L3

=> d ibib abs fhitstr 1-2

L4   ANSWER 1 OF 2  CA  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         143:26605  CA
TITLE:                    Preparation of imidazolyl hydroxylamine derivatives as
                          antitumor and antiviral agents
INVENTOR(S):              Kshirsagar, Tushar A.; Lundquist, Gregory D., Jr.;
                          Amos, David T.; Dellaria, Joseph F., Jr.; Zimmermann,
                          Bernhard M.; Heppner, Philip D.
PATENT ASSIGNEE(S):       3M Innovative Properties Company, USA
SOURCE:                   PCT Int. Appl., 230 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2005048945         A2    20050602    WO 2004-US38033         20041112
     WO 2005048945         A3    20060323
```

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004291122	A1	20050602	AU 2004-291122		20041112
CA 2545825	A1	20050602	CA 2004-2545825		20041112
EP 1682544	A2	20060726	EP 2004-810969		20041112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU					
CN 1906192	A	20070131	CN 2004-80040435		20041112
JP 2007511535	T	20070510	JP 2006-539957		20041112
US 20090105295	A1	20090423	US 2006-595790		20060511
IN 2006CN01680	A	20070824	IN 2006-CN1680		20060512
PRIORITY APPLN. INFO.:			US 2003-520215P	P	20031114
			WO 2004-US38033	W	20041112

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:26605; MARPAT 143:26605
GI



I



II

AB Title compds. I [X = alkylene, alkenylene; R1 and R2 independently = H, halo, alkoxy, etc. or R1 and R2 together = (un)substituted fused-aryl or -heteroaryl ring, fused 5 to 7-membered (un)substituted-saturated ring optionally containing one heteroatom (N or S); R3 = H or non-interfering substituents; R4 = (un)substituted amine, heterocycle containing at least one

nitrogen atom and optionally sulfur] and their pharmaceutically acceptable salts, are prepared and disclosed as antitumor and antiviral agents. Thus, e.g., II was prepared by cyclization of N4-(2-methylpropyl)quinoline-3,4-diamine with chloroacetyl chloride to the resp. imidazolyl quinoline intermediate, which was aminated to give 2-chloromethyl-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine (III). III was then reacted with N-hydroxyphthalimide to provide the N-phthalimide protected hydroxylamine derivative which is deprotected using hydrazine and then converted into its HCl salt. The ability of I to induce cytokine biosynthesis was evaluated and selected compds. of the invention may display inhibition of tumor necrosis factor α (TNF-α) (no data given). I as inhibitor of tumor necrosis factor α should prove useful in the treatment of neoplastic and viral diseases.

IT 852718-30-0
RL: PRPH (Prophetic)
(Preparation of imidazolyl hydroxylamine derivatives as antitumor and antiviral agents)

RN 852718-30-0 CA

CN Acetamide, N-[[4-amino-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinolin-2-yl]methoxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L4 ANSWER 2 OF 2 CA COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 143:26604 CA

TITLE: Preparation of oxime substituted imidazo-containing compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease

INVENTOR(S): Kshirsagar, Tushar A.; Lundquist, Gregory D., Jr.; Amos, David T.; Dellaria, Joseph F., Jr.; Zimmermann, Bernhard M.; Heppner, Philip D.

PATENT ASSIGNEE(S): 3M Innovative Properties Company, USA

SOURCE: PCT Int. Appl., 316 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2005048933	A2	20050602	WO 2004-US37854		20041112
WO 2005048933	A3	20051201			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004291101	A1	20050602	AU 2004-291101		20041112
CA 2545774	A1	20050602	CA 2004-2545774		20041112
EP 1685129	A2	20060802	EP 2004-810872		20041112

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

CN 1906193	A	20070131	CN 2004-80040434		20041112
JP 2007511527	T	20070510	JP 2006-539911		20041112
US 20090042925	A1	20090212	US 2006-595792		20060511
IN 2006CN01669	A	20070810	IN 2006-CN1669		20060512
PRIORITY APPLN. INFO.:			US 2003-520418P	P	20031114
			WO 2004-US37854	W	20041112

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:26604; MARPAT 143:26604

GI



I



II

AB Title compds. [I; X = alk(en)ylene; RA, RB = independently H, halo, alk(en)yl, alkoxy, alkylthio, NH2 and derivs.; RACH-CHRB = (un)substituted fused hetero/aryl ring; RACH-CHRB = (un)substituted fused 5-7-membered

saturated ring; R2, R'' = independently H, (un)substituted alk(en)yl, hetero/aryl, hetero/arylalkylenyl, heterocyclylalkylenyl; or R2CR'' = (un)substituted 4-9-membered ring; R' = H, non-interfering substituent], were prepared as immunomodulators for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases. A 5-step synthesis for II is given. I may modulate cytokine biosynthesis by inhibiting production of tumor necrosis factor TNF-α when tested in mouse cells (no data).

IT 1044959-53-6
RL: PRPH (Prophetic)
(Preparation of oxime substituted imidazo-containing compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)

RN 1044959-53-6 CA
CN INDEX NAME NOT YET ASSIGNED



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file marpat
C
US 20090275099 05 NOV 2009
DE 102008020044 22 OCT 2009
EP 2110380 21 OCT 2009
JP 2009267138 12 NOV 2009
WO 2009137964 19 NOV 2009
GB 2459133 14 OCT 2009
FR 2930247 23 OCT 2009
RU 2371517 27 OCT 2009
CA 2653107 08 AUG 2009

The new MARPAT User Guide is now available at:
http://www.cas.org/support/stngen/stndoc/marpat.html.

```
=> s l3 full
FULL SEARCH INITIATED 15:08:32 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -      5745 TO ITERATE

100.0% PROCESSED     5745 ITERATIONS                                  4 ANSWERS
SEARCH TIME: 00.00.04

L5             4 SEA SSS FUL L1

=> d ibib abs fqhit 1-4

L5   ANSWER 1 OF 4  MARPAT  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         148:79028  MARPAT
TITLE:                    Ring closing and related methods and intermediates
                          useful in making imidazoquinolinamines and
                          imidazonaphthyridinamines
INVENTOR(S):              Hays, David S.; Mackey, Sonja S.; Moser, William H.;
                          Stoermer, Doris; Radmer, Matthew R.; Niwas, Shri
PATENT ASSIGNEE(S):       Coley Pharmaceutical Group, Inc., USA
SOURCE:                   PCT Int. Appl., 123pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND  DATE          APPLICATION NO.  DATE
     ----------------    ----  --------      ---------------  --------
     WO 2006121528        A2   20061116      WO 2006-US12022  20060331
     WO 2006121528        A3   20070913
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AP, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             EA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, EP, AT, BE, BG, CH, CY,
             CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV,
             MC, NL, PL, PT, RO, SE, SI, SK, TR, OA, BF, BJ, CF, CG, CI, CM,
             GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2602853           A1   20061116      CA 2006-2602853  20060331
     EP 1863770           A2   20071212      EP 2006-769789   20060331
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
             BA, HR, MK, YU
     JP 2008535831        T    20080904      JP 2008-504436   20060331
PRIORITY APPLN. INFO.:                      US 2005-667840P  20050401
                                            WO 2006-US12022  20060331
OTHER SOURCE(S):          CASREACT 148:79028
GI
```



I



II



III



IV



V

AB Methods and intermediates useful for making compds. I [R1, R2 = H, alkyl, aryl, etc.; R3 and R4 taken together form (un)substituted fused benzene ring or fused pyridine ring], and the preparation of compds. I, preferably including the formation of intermediate [II or III; R1, R2 are defined as above; D = CN, CO2alkyl, CONH2, CHO, CH2OH, CH2Oalkyl; E = Cl, Br, I, OSO2CF3 and N2+BF4-; M = B(OH)2, B(Oalkyl)2, Sn(alkyl)3, etc.], were provided. For example, treating aminomalononitrile p-toluenesulfonate with dry ammonia in MeCN followed by addition of tri-Me orthoacetate, and subsequently N,N-disisopropylethylamine and methylamine hydrochloride afforded 5-amino-1,2-dimethyl-1H-imidazole-4-carbonitrile which was converted to 5-bromo-1,2-dimethyl-1H-imidazole-4-carbonitrile (IV). Coupling of 2-aminophenylboronic acid with IV followed by cyclization of the resulting 5-(2-aminophenyl)-1,2-dimethyl-1H-imidazole-4-carbonitrile afforded the imidazoquinolinamine V.HCl.

MSTR 3



G21 = carbon chain <containing 1-20 C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd.)
G22 = 240-142 210-144



G23 = NH (opt. substd.)
G35 = 142 / 145



G36 = G35
G42 = G35
G1 +G2 = CH=CHCH=CH (opt. substd. by 1 or more G6)
Patent location: claim 1
Note: substitution is restricted
Note: additional derivatization also claimed

L5 ANSWER 2 OF 4 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 146:358853 MARPAT
TITLE: Process for preparation of (fused) 1H-imidazo[4,5-c]pyridines by cyclocondensation of acylaminoquinolines with primary amines.
INVENTOR(S): Krepski, Larry R.; Marszalek, Gregory J.; Mackey, Sonja S.; Gerster, John F.
PATENT ASSIGNEE(S): 3M Innovative Properties Company, USA
SOURCE: PCT Int. Appl., 135pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007035935	A1	20070329	WO 2006-US37317	20060922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006292119	A1	20070329	AU 2006-292119	20060922
CA 2623541	A1	20070329	CA 2006-2623541	20060922
EP 1937683	A1	20080702	EP 2006-815370	20060922
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

JP 2009509971	T	20090312	JP 2008-532484	20060922
MX 2008004012	A	20080603	MX 2008-4012	20080324
IN 2008DN02448	A	20080627	IN 2008-DN2448	20080324
ZA 2008002824	A	20081231	ZA 2008-2824	20080331
KR 2008048551	A	20080602	KR 2008-709576	20080422
CN 101312975	A	20081126	CN 2006-80043878	20080523
US 20090240055	A1	20090924	US 2009-992371	20090506
PRIORITY APPLN. INFO.:			US 2005-720171P	20050923
			US 2006-743505P	20060316
			WO 2006-US37317	20060922

OTHER SOURCE(S): CASREACT 146:358853

GI



I



II

AB Title compds. [I; E = H, F, Cl, Br, iodo, OH, Ph, N(Bn)2, etc.; Bn = PhCH2, p-methoxybenzyl, p-methylbenzyl, 2-furylmethyl; E may form a ring with the adjacent pyridine N atom to form a tetrazolo ring; Ra, Rb = H, halo, alkyl, alkenyl, alkoxy, alkylthio, amino; RaRb = atoms to form a fused ring; R1 = R4, XR4, XYR4, XYXYR4, XR5, etc.; R2 = R4, XR4, XYR4, XR5; X = (substituted) alkylene, alkenylene, alkynylene, arylene, heteroarylene, heterocyclylene; Y = O, S, SO, SO2, OCO2, etc.; R4 = H, alkyl, alkenyl, alkynyl, aryl, aralkenyl, heteroaryl, etc.; R5 = specified (hetero)cyclyl], were prepared by reaction of acylaminoquinolines (II; L = F, Cl, Br, iodo, PhO, alkylsulfonyl, arylsulfonyl; other variables as above) with R1NH2 (R1 as above). Thus, N-(4-chloroquinolin-3-yl)-2-ethoxyacetamide (preparation given), 1-amino-2-methylpropan-2-ol, and p-toluenesulfonic acid were heated together at 125° for 15 h in a pressure vessel to give 1-[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol. Treatment of the latter with m-CPBA in CH2Cl2 and then with trichloroacetyl isocyanate in CH2Cl2 to give 1-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol.

MSTR 2

G1—G35
287

G1 = 2

G46–G13
2 3

G2 = NH2
G13 = 246 / 250 / 253

G17–G18 (246) G17–G19–G18 (250) G17–G20 (253)

G17 = carbon chain <containing 1-20 C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd.)
G20 = 279



G35 = 300 / 302 / 305

G17–G18 (300) G17–G36–G18 (302, 304) G17–G20 (305)

G46 = 403-287 402-3



G47 = N
Patent location: claim 1
Note: or pharmaceutically acceptable salts
Note: also incorporates later claims
Note: substitution is restricted

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 143:26605 MARPAT
TITLE: Preparation of imidazolyl hydroxylamine derivatives as antitumor and antiviral agents
INVENTOR(S): Kshirsagar, Tushar A.; Lundquist, Gregory D., Jr.; Amos, David T.; Dellaria, Joseph F., Jr.; Zimmermann,

	Bernhard M.; Heppner, Philip D.
PATENT ASSIGNEE(S):	3M Innovative Properties Company, USA
SOURCE:	PCT Int. Appl., 230 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005048945	A2	20050602	WO 2004-US38033	20041112
WO 2005048945	A3	20060323		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004291122	A1	20050602	AU 2004-291122	20041112
CA 2545825	A1	20050602	CA 2004-2545825	20041112
EP 1682544	A2	20060726	EP 2004-810969	20041112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
CN 1906192	A	20070131	CN 2004-80040435	20041112
JP 2007511535	T	20070510	JP 2006-539957	20041112
US 20090105295	A1	20090423	US 2006-595790	20060511
IN 2006CN01680	A	20070824	IN 2006-CN1680	20060512
PRIORITY APPLN. INFO.:			US 2003-520215P	20031114
			WO 2004-US38033	20041112

OTHER SOURCE(S): CASREACT 143:26605
GI



I



II

AB Title compds. I [X = alkylene, alkenylene; R1 and R2 independently = H, halo, alkoxy, etc. or R1 and R2 together = (un)substituted fused-aryl or -heteroaryl ring, fused 5 to 7-membered (un)substituted-saturated ring optionally containing one heteroatom (N or S); R3 = H or non-interfering substituents; R4 = (un)substituted amine, heterocycle containing at least one nitrogen atom and optionally sulfur] and their pharmaceutically acceptable salts, are prepared and disclosed as antitumor and antiviral agents. Thus, e.g., II was prepared by cyclization of N4-(2-methylpropyl)quinoline-3,4-diamine with chloroacetyl chloride to the resp. imidazolyl quinoline intermediate, which was aminated to give 2-chloromethyl-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine (III). III was then reacted with N-hydroxyphthalimide to provide the N-phthalimide protected hydroxylamine derivative which is deprotected using hydrazine and then converted into its HCl salt. The ability of I to induce cytokine biosynthesis was evaluated and selected compds. of the invention may display inhibition of tumor necrosis factor α (TNF-α) (no data given). I as inhibitor of tumor necrosis factor α should prove useful in the treatment of neoplastic and viral diseases.

MSTR 1



G1 = carbon chain <containing 1-10 C, 0 or more double bonds, no triple bonds>

G6 = 13



G9 = heterocycle <containing zero or more N,
zero or more O, zero or more S (no other heteroatoms),
0 or more double bonds> (opt. substd. by 1 or more G21)
G22+G23= 108-7 111-6



Patent location: claim 1
Note: or pharmaceutically acceptable salts
Note: substitution is restricted
Note: additional heteroatom interruption also claimed
Note: additional ring formation also claimed
Note: also incorporates later claims

L5 ANSWER 4 OF 4 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 143:26604 MARPAT
TITLE: Preparation of oxime substituted imidazo-containing compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease
INVENTOR(S): Kshirsagar, Tushar A.; Lundquist, Gregory D., Jr.; Amos, David T.; Dellaria, Joseph F., Jr.; Zimmermann, Bernhard M.; Heppner, Philip D.
PATENT ASSIGNEE(S): 3M Innovative Properties Company, USA
SOURCE: PCT Int. Appl., 316 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005048933	A2	20050602	WO 2004-US37854	20041112
WO 2005048933	A3	20051201		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,

NE, SN, TD, TG
AU 2004291101 A1 20050602 AU 2004-291101 20041112
CA 2545774 A1 20050602 CA 2004-2545774 20041112
EP 1685129 A2 20060802 EP 2004-810872 20041112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
CN 1906193 A 20070131 CN 2004-80040434 20041112
JP 2007511527 T 20070510 JP 2006-539911 20041112
US 20090042925 A1 20090212 US 2006-595792 20060511
IN 2006CN01669 A 20070810 IN 2006-CN1669 20060512
PRIORITY APPLN. INFO.: US 2003-520418P 20031114
WO 2004-US37854 20041112
OTHER SOURCE(S): CASREACT 143:26604
GI



I



II

AB Title compds. [I; X = alk(en)ylene; RA, RB = independently H, halo, alk(en)yl, alkoxy, alkylthio, NH2 and derivs.; RACH-CHRB = (un)substituted fused hetero/aryl ring; RACH-CHRB = (un)substituted fused 5-7-membered saturated ring; R2, R'' = independently H, (un)substituted alk(en)yl, hetero/aryl, hetero/arylalkylenyl, heterocyclylalkylenyl; or R2CR'' = (un)substituted 4-9-membered ring; R' = H, non-interfering substituent], were prepared as immunomodulators for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases. A 5-step synthesis for II is given. I may modulate cytokine biosynthesis by inhibiting production of tumor necrosis factor TNF-α when tested in mouse cells (no data).

MSTR 1



G1 = carbon chain <containing 1-10 C,
0 or more double bonds, no triple bonds>
G5 = 202



G6 = 276



G50 = 8-7 9-1



G22+G23= 108-7 111-6



Patent location: claim 1
Note: or pharmaceutically acceptable salts
Note: substitution is restricted
Note: additional heteroatom interruption also claimed
Note: additional ring formation also claimed
Note: also incorporates later claims

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:04:07 ON 14 DEC 2009)

FILE 'REGISTRY' ENTERED AT 15:04:19 ON 14 DEC 2009
L1 STRUCTURE UPLOADED
L2 24 S L1 SAM

```
L3           476 S L1 FULL

     FILE 'CA' ENTERED AT 15:05:45 ON 14 DEC 2009
L4             2 S L3

     FILE 'MARPAT' ENTERED AT 15:08:27 ON 14 DEC 2009
L5             4 S L3 FULL

=>

---Logging off of STN---


=>
Executing the logoff script...

=> LOG Y

COST
STN INTERNATIONAL LOGOFF AT 15:09:46 ON 14 DEC 2009
```